R5XA Stock Overview
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Talphera, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.94 |
52 Week High | US$1.33 |
52 Week Low | US$0.39 |
Beta | 0.48 |
1 Month Change | 5.72% |
3 Month Change | 2.28% |
1 Year Change | 71.14% |
3 Year Change | -94.86% |
5 Year Change | -98.38% |
Change since IPO | -98.49% |
Recent News & Updates
Recent updates
Shareholder Returns
R5XA | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -8.3% | 0.9% | -1.0% |
1Y | 71.1% | -27.7% | 2.0% |
Return vs Industry: R5XA exceeded the German Pharmaceuticals industry which returned -27.9% over the past year.
Return vs Market: R5XA exceeded the German Market which returned 2.5% over the past year.
Price Volatility
R5XA volatility | |
---|---|
R5XA Average Weekly Movement | 14.8% |
Pharmaceuticals Industry Average Movement | 7.2% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: R5XA's share price has been volatile over the past 3 months.
Volatility Over Time: R5XA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 15 | Vince Angotti | talphera.com |
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
Talphera, Inc. Fundamentals Summary
R5XA fundamental statistics | |
---|---|
Market cap | €16.10m |
Earnings (TTM) | -€9.56m |
Revenue (TTM) | €604.71k |
26.6x
P/S Ratio-1.7x
P/E RatioIs R5XA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
R5XA income statement (TTM) | |
---|---|
Revenue | US$651.00k |
Cost of Revenue | US$498.00k |
Gross Profit | US$153.00k |
Other Expenses | US$10.44m |
Earnings | -US$10.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | -0.61 |
Gross Margin | 23.50% |
Net Profit Margin | -1,580.18% |
Debt/Equity Ratio | 0% |
How did R5XA perform over the long term?
See historical performance and comparison